The retail drug price medical insurance bureau is going to take care of it

Source: sepiland - pharmacy Manager ▍ arrangement: Xiyu The state health insurance bureau issued a document to start the work of drug supply and price stabilization Once the price of drugs is found to be abnormal, it is necessary to consult the relevant operators and ask for a written explanation If the reason for price increase is unreasonable, insufficient and refuses to adjust, it will be punished accordingly On December 6, the state health insurance bureau issued the opinions on the current drug price management (hereinafter referred to as "opinions") The opinion is clear that the price range of drugs managed by the medical security department includes chemical drugs, proprietary Chinese medicine, biochemical drugs, Chinese herbal pieces, preparations of medical institutions, etc Among them, the price of narcotic drugs and the first category of psychotropic drugs shall be guided by the government, and the price of other drugs shall be regulated by the market As for how to price, the opinion requires that drug dealers (including listing license holders, production and trading enterprises, etc., the same below) should follow the principles of fairness, legality, good faith and consistency of quality and price to make drug prices reflect cost changes and market supply and demand, and maintain reasonable and stable prices If there are differences in dosage forms, specifications and packaging of the same kind of drugs, according to the principle of equal treatment costs, comprehensive consideration of clinical effect, cost value, technical level and other factors, to maintain a reasonable price difference relationship The specific rules shall be separately formulated by the State Medical Security Bureau During the transition period, in pricing, purchasing and payment, if the conversion of drug price difference relationship is involved, please refer to the implemented rules Secondly, the opinion also emphasizes that we should give full play to the guiding role of medical insurance in drug price, adhere to the direction of "purchasing with quantity, linking with quantity and price, and integrating bidding and purchasing", and promote the drug price to return to a reasonable level In addition, we should improve the agreement management of designated institutions, strengthen the price supervision and information disclosure of drugs paid by medical insurance funds, and positively guide the market price order If according to the above requirements, it also means that in addition to the reasonable formulation of drug prices, the medical insurance bureau will also manage drug prices through centralized purchase, medical insurance payment and other ways In view of the current situation, it may be understood that drugs with high prices can be reduced In fact, the medical insurance bureau has taken actions on the control of drug prices for a long time, not to mention volume purchase, negotiation and price negotiation This year, Quanzhou Medical Insurance Bureau in Fujian Province and Xianning Medical Insurance Bureau in Hubei Province have taken relevant actions to directly regulate the retail drug prices For example, Quanzhou in Fujian Province monitors the price of 100 commonly used drugs in 15 fixed-point chain retail pharmacies in the city, updates and publishes the retail price of drugs on a quarterly basis, so that the masses can query the price information of various drugs in a timely manner; Xianning in Hubei Province is more direct, with the encouragement of the city's Medical Insurance Bureau, several Dalian locks respond positively, and reduce the price of 100 commonly sold drugs in the pharmacies, with an average decrease of 6.01%, some of them The highest decrease of varieties was 46.67% In addition, the Opinions also clearly put forward that it is necessary to establish and improve the regulatory mechanism for the normalization of drug prices On the basis of respecting the market rules and the independent pricing power of operators, it is necessary to comprehensively use monitoring and early warning, correspondence and interview, reminding and warning, cost investigation, credit evaluation, information disclosure and other means to establish and improve the regulatory mechanism for the normalization of drug prices and promote the operators to strengthen price self-discipline It is mainly through the establishment of monitoring and early warning mechanism for abnormal changes in price supply, strengthening daily management by means of letters, inquiries and interviews, improving the work mechanism of drug price cost investigation, exploring the establishment of trustworthy incentive and dishonest punishment mechanism, and strengthening social supervision by means of information disclosure It mainly involves the following contents: 1 For drugs with abnormal price increase or frequency, large price difference between regions or between online and offline, obvious price increase in circulation link beyond reasonable level, and inadequate distribution, medical security departments at all levels can ask relevant operators for written explanation 2 If the circumstances are serious and the impact is bad, the relevant operators can be interviewed or cross regional joint interviews to explain the reasons for the changes, provide the production, operation, financial and product flow information related to the composition of drug price cost, and properly deal with them by classification.